The efficacy of metformin in the treatment of type 2 diabetes
https://doi.org/10.21518/2079-701X-2016-3-30-37
Abstract
Diabetes mellitus (DM) is a serious medical and social problem. The prevalence of diabetes has been steadily increasing in all countries, where 95% are patients with type 2 diabetes. According to the International Diabetes Federation, in 2014, the number of patients with type 2 diabetes was 387 million, or every 12th inhabitant of the planet. By 2035, the number of patients with type 2 diabetes could increase to 592 million people [1]. Global trends in diabetes incidence rates are also observed in Russia. According to the national register, there are 8 million diabetic patients in Russia, or approximately 5% of the total population, whereas 90% of them are patients with type 2 diabetes. By 2025, the number of patients is expected to increase to 13 million people. The number of registered patients is usually 2-3 times less than the real number. [2, 3] The greatest input in the number of diabetic patients is made by the increase in the number of type 2 diabetes patients in older age groups.
About the Authors
А. S. Ametov
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
T. Y. Demidova
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
I. I. Kochergina
Russian Medical Academy of Postgraduate Education
Russian Federation
Russian Federation
References
1. Diabetes Atlas IDF 2014, 5th ed. http//www.idf. org/diabetesatlas/ 5e/the-globalburden.
2. Сунцов Ю.И., Дедов И.И., Кудрякова С.В. Государственный регистр сахарного диабета: эпидемиологическая характеристика инсулиннезависимого сахарного диабета. Сахарный диабет, 2002, 1: 41-3
3. Структура сердечнo-сосудистой заболеваемости и смертности в РФ за 2004 г. Клиническая медицина, 2005, 1: 3-8.
4. Haffner SM, Lehto S., Ronnemaa T., Mortality from coronary artery disease in subject with type 2 diabetes and nondiabetic subjects with and without myocardial infarction. N Engl. J Med., 1998, 339:-229-234.
5. Мычка В.Б., Чазова И.Е. Сердечно-сосудистые осложнения сахарного диабета типа 2. Consilium Medicum, 2003, 5(9): 504-509.
6. Neaton JD, Wentworth DN, Cutler J, Kuller L. Risk factors for death from different types of stroke. Multiple Risk Factor Intervention trial Research Group. Ann Epidemiol, 1993, 3: 493-499.
7. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J Med, 1993, 329: 977-986.
8. UK Prospective Diabetes Study Group. Tight Blood pressure control and risk of microvascular and microvascular complications in type 2 diabetes: (UKPDS 38). BMJ, 1998, 317: 703-13.
9. Fruhbeek G, Salvador J. Relation between leptin and regulatic of glucose metabolism. Diabetologia, 2000, 43(1): 3-12.
10. Trujillo ME, Scherer PE Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J intern Med, 2005, 257: 167-175.
11. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol, 2004, 15: 2792-80.
12. Rosen ED, Spiegelman BM. Tumor necrosis factor as a mediator of insulin resistance of obesity. Curr opin Endocrinol Metab, 1999, 6: 170-176.
13. Sevter CP, Digby JE еt al. Regulation of tumor necrosis factor-alpha release from human adipose tissue in vitro. J Endocrinol, 1999, 163: 33-38.
14. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS). Lancet, 1998, 352: 854-65.
15. Tuomilehto J, Lindstrom J, Ericsson J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Eng J Med, 2001, 344: 1343-50.
16. Jonson AB, Webster JM. SUM CF The impact of metformin therapy on hepatic glucose production end skeletal muscule glycogen synthase activity in overweight type 2 diabetes patients. Metabolism, 1993, 42: 1217-22.
17. Eurich DT, Majumdar SR et al. Impruved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabet Care, 2005, 28: 2345-51.
18. Salpeter SR, Greyber E et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analisis. Arch intern Med, 2003, 163(21): 2594-602.
19. Buck ML. Use of Metformin in Pediatric Pacients. Pediatr Pharm, 2004, 10(7).
20. Suntsov Y.I., Dedov I.I., Kudriakov S.V., The State Register of Diabetes: epidemiological characteristics of non-insulin dependent diabetes mellitus. Sakharniy Diabet, 2002, 1: 41-3
21. The structure of cardiovascular morbidity and mortality in the Russian Federation in 2004. Klinicheskaya Meditsina, 2005, 1: 3-8.
22. Mychka V.B., Chazova I.E. Cardiovascular complications of type 2 diabetes. Consilium Medicum, 2003, 5(9): 504-509.
Review
For citations:
Ametov АS, Demidova TY, Kochergina II. The efficacy of metformin in the treatment of type 2 diabetes. Meditsinskiy sovet = Medical Council. 2016;(3):30-37. (In Russ.) https://doi.org/10.21518/2079-701X-2016-3-30-37
Views:
740
Email this article 